Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-02-12 00:00:00 ET · period of report 2026-02-10 · accession 0000875320-26-000048 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-12 | 2026-02-10 | VRTX | McKechnie Duncan | EVP, Chief Commercial Off | F - Tax | $468.41 | -1,127 | 21.8K | -5% | -$527.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-10 | F | D | 1,127 | $468.41 | 21,811 | D | — | — |